A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
Paul M Karpecki,1,2 Sidney L Weiss,3 William G Kramer,4 Patrick O’Connor,5 David Evans,6 Josh Johnston,7 April L Jasper,8 Angela Justice,9 Abayomi B Ogundele,9 Doug Devries10 1Kentucky Eye Institute, Lexington, KY, USA; 2Gaddie Eye Centers, Louisville, KY, USA; 3i-novion, Inc., Randolph,...
Saved in:
Main Authors: | Karpecki PM, Weiss SL, Kramer WG, O'Connor P, Evans D, Johnston J, Jasper AL, Justice A, Ogundele AB, Devries D |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/f8bebe97bc844400bd124f7bbbe0f33a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
by: Sheppard J, et al.
Published: (2021) -
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
by: Li Y, et al.
Published: (2020) -
A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
by: Periman LM, et al.
Published: (2020) -
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
by: Tauber J, et al.
Published: (2018) -
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
by: White DE, et al.
Published: (2019)